...
首页> 外文期刊>ASAIO journal >First Successful Treatment of Coronavirus Disease 2019 Induced Refractory Cardiogenic Plus Vasoplegic Shock by Combination of Percutaneous Ventricular Assist Device and Extracorporeal Membrane Oxygenation: A Case Report
【24h】

First Successful Treatment of Coronavirus Disease 2019 Induced Refractory Cardiogenic Plus Vasoplegic Shock by Combination of Percutaneous Ventricular Assist Device and Extracorporeal Membrane Oxygenation: A Case Report

机译:首次成功治疗冠状病毒疾病2019诱导难治性心脏发生加压震动,通过经皮室辅助装置和体外膜氧合组合:案例报告

获取原文
获取原文并翻译 | 示例
           

摘要

The novel coronavirus severe acute respiratory syndrome coronavirus 2 is infecting hundreds of thousands of humans around the globe. The coronavirus disease 2019 (COVID-19) is known to generate mild as well as critical courses. Complications on the intensive care units include acute respiratory distress syndrome, acute cardiac, and kidney injury as well as shock. Here, we present the first case report of a successful treatment of a COVID-19 patient presenting with adult respiratory distress syndrome plus refractory combined cardiogenic and vasoplegic shock, which could be successfully stabilized after implantation of a percutaneous ventricular assist device plus an extracorporeal membrane oxygenation. Although such intense treatment might not be feasible in case of a health care disaster as described for the hot spots of the COVID-19 pandemic, it might encourage treatment of younger patients on intensive care units not overcrowded by critically ill patients.
机译:新型冠状病毒严重急性呼吸综合征冠状病毒2感染了全球数十万人。 已知冠状病毒疾病2019(Covid-19)产生轻度以及批判性课程。 密集护理单位的并发症包括急性呼吸窘迫综合征,急性心脏和肾脏损伤以及休克。 在这里,我们提出了第一种案例报告,患有成人呼吸窘迫综合征的Covid-19患者的成功治疗案例报告加耐火组合的心脏生成和缓冲休克,该休克可以在植入经皮心室辅助装置和体外膜氧合后成功稳定 。 虽然如康复-19大流行的热点所描述的医疗保健灾难,但这种强烈的治疗可能是不可行的,但它可能会鼓励对患者未经危重的患者过度拥挤的重症监护单位对年轻患者的治疗。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号